|
|
???tair.name??? >
???browser.page.title.author???
|
"okusaka t"???jsp.browse.items-by-author.description???
Showing items 1-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國立成功大學 |
2023 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, D.-Y.;He, A.R.;Qin, S.;Chen, L.-T.;Okusaka, T.;Vogel, A.;Kim, J.W.;Suksombooncharoen, T.;Lee, M.A.;Kitano, M.;Burris, H.;Bouattour, M.;Tanasanvimon, S.;McNamara, McNamara M.G.;Zaucha, R.;Avallone, Avallone A.;Tan, B.;Cundom, J.;Lee, C.-K.;Takahashi, H.;Ikeda, M.;Chen, J.-S.;Wang, J.;Makowsky, Makowsky M.;Rokutanda, N.;Żotkiewicz, M.;Kurland, J.F.;Cohen, G.;Valle, J.W. |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 臺大學術典藏 |
2021-09-01T01:53:48Z |
Randomized phase iii study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest study
|
Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 國家衛生研究院 |
2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
|
Oh, DY;Chen, LT;He, AR;Okusaka, T;Qin, S;Chin, S;Rokutanda, N;Uchinda, H;Vogel, A;Valle, JW;Kim, H |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
| 國立成功大學 |
2014-11 |
Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary antitumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma
|
Kang, Y. K.; Ryoo, BY; Kim, TY; Lee, KH; Lim, HY; Lee, SJ; Ikeda, M; Okusaka, T; Nadano, S; Lin, CC; Poon, TP; Yen, CJ; McCoon, P; Neumann, F; Vishwantahan, K; DuPont; Lyne, P |
Showing items 1-18 of 18 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
